Oral montelukast in acute asthma exacerbations: A randomised, double-blind, placebo-controlled trial

Thorax

Volumn 66, Issue 1, 2011, Pages 7-11

  Ramsay, Crichton F ^a   Pearson, Darcy ^a   Mildenhall, Sue ^a   Wilson, Andrew M ^a,b  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; IPRATROPIUM BROMIDE; MAGNESIUM; MONTELUKAST; PLACEBO; PREDNISOLONE; SALBUTAMOL; THEOPHYLLINE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG FATALITY; EVENING DOSAGE; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 78650185854     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2010.135038     Document Type: Article

References (30)

1. British guideline on the management of asthma. Thorax 2003;58(Suppl 1):i1-94. Revised 2008 and 2009.
2. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Updated 2009. http://www.ginasthma.com.
3. Kemp JP, Minkwitz MC, Bonuccelli CM, et al. Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma. Chest 1999;115:336-42.
4. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998;158:1213-20.
5. Kuitert LM, Barnes NC. Leukotriene receptor antagonists: useful in acute asthma? Thorax 2000;55:255-6.
6. Drazen JM, O'Brien J, Sparrow D, et al. Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992;146:104-8.
7. Green SA, Malice MP, Tanaka W, et al. Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation. Thorax 2004;59:100-4. (Pubitemid 38223478)
8. Taylor GW, Taylor I, Black P, et al. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989;1:584-8.
9. Schwartzberg SB, Shelov SP, Van Praag D. Blood leukotriene levels during the acute asthma attack in children. Prostaglandins Leukot Med 1987;26:143-55.
10. Sampson AP, Castling DP, Green CP, et al. Persistent increase in plasma and urinary leukotrienes after acute asthma. Arch Dis Child 1995;73:221-5.
11. Lammers JW, Van Daele P, Van den Elshout FM, et al. Bronchodilator properties of an inhaled leukotriene D4 antagonist (verlukasteMK-0679) in asthmatic patients. Pulm Pharmacol 1992;5:121-5.
12. Dockhorn RJ, Baumgartner RA, Leff JA, et al. Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients. Thorax 2000;55:260-5.
13. Gaddy JN, Margolskee DJ, Bush RK, et al. Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 1992;146:358-63.
14. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991;337:1062-3.
15. Camargo CA Jr, Smithline HA, Malice MP, et al. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 2003;167:528-33.
16. Silverman RA, Nowak RM, Korenblat PE, et al. Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial. Chest 2004;126:1480-9.
17. Harmanci K, Bakirtas A, Turktas I, et al. Oral montelukast treatment of preschoolaged children with acute asthma. Ann Allergy Asthma Immunol 2006;96:731-5. (Pubitemid 43749007)
18. Ferreira MB, Santos AS, Pregal AL, et al. Leukotriene receptor antagonists (Montelukast) in the treatment of asthma crisis: preliminary results of a double-blind placebo controlled randomized study. Allerg Immunol (Paris) 2001;33:315-18.
19. Cylly A, Kara A, Ozdemir T, et al. Effects of oral montelukast on airway function in acute asthma. Respir Med 2003;97:533-6.
20. Innes NJ, Stocking JA, Daynes TJ, et al. Randomised pragmatic comparison of UK and US treatment of acute asthma presenting to hospital. Thorax 2002;57:1040-4.
21. Bradshaw TA, Matusiewicz SP, Crompton GK, et al. Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respir Med 2008;102:143-9.
22. Mohammed S, Goodacre S. Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis. Emerg Med J 2007;24:823-30. (Pubitemid 350200629)
23. Porter RS, Nester BA, Braitman LE, et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. Eur J Emerg Med 2001;8:9-15.
24. Rodrigo G, Rodrigo C, Burschtin O. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. Am J Med 1999;107:363-70.
25. Rodrigo GJ, Rodrigo C. IV magnesium in the treatment of acute severe asthma? Chest 2003;123:1314-15; author reply 5-6.
26. Rowe BH, Camargo CA Jr. The role of magnesium sulfate in the acute and chronic management of asthma. Curr Opin Pulm Med 2008;14:70-6.
27. D'Avila RS, Piva JP, Marostica PJ, et al. Early administration of two intravenous bolus of aminophylline added to the standard treatment of children with acute asthma. Respir Med 2008;102:156-61.
28. Silverman RA, Osborn H, Runge J, et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest 2002;122:489-97.
29. Stoodley RG, Aaron SD, Dales RE. The role of ipratropium bromide in the emergency management of acute asthma exacerbation: a metaanalysis of randomized clinical trials. Ann Emerg Med 1999;34:8-18.
30. Zainudin BM, Ismail O, Yusoff K. Effect of adding aminophylline infusion to nebulised salbutamol in severe acute asthma. Thorax 1994;49:267-9.